LUCICEBTIDE (ST101) MECHANISM OF ACTION March 3, 2025The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responsesSeptember 19, 2022Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein β C/EBPβ LITERATURE December 15, 2020STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathwayMay 14, 2020Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβDecember 23, 2009The transcriptional network for mesenchymal transformation of brain tumorsSeptember 1, 2008Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cellsMarch 1, 2006Increased expression of CCAAT/enhancer binding protein ß correlates with prognosis in glioma patients β‑CATENIN LITERATURE October 11, 2021WNT as a driver and dependency in cancerMay 8, 2020Wnts and the hallmarks of cancerSeptember 30, 2019Targeting the Wnt signalling pathway in cancer: prospects and perilsJune 11, 2019β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular CarcinomaOctober 30, 2015BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer
